Overview

A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Course

Status:
Completed

Trial end date:
2018-04-23

Target enrollment:

Participant gender:

Summary

Treatment of patients with WHO defined IPSS int 2 and high risk MDS , AML with 20-30% marrow blasts and CMML type 2, after failure of azacitidine or decitabine exposure for at least 6 courses, or relapse after initial response.

Phase:

Phase 2

Details

Lead Sponsor:

Groupe Francophone des Myelodysplasies

Collaborators:

Astex Pharmaceuticals
Astex Pharmaceuticals, Inc.

Treatments:

Azacitidine
Decitabine
Guadecitabine